Equities analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to post sales of $5.39 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with estimates ranging from $4.14 million to $6.53 million. BioCryst Pharmaceuticals reported sales of $4.79 million in the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The company is scheduled to report its next earnings report before the market opens on Monday, August 7th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $5.39 million for the current year, with estimates ranging from $21.85 million to $32.95 million. For the next year, analysts expect that the business will post sales of $28.41 million per share, with estimates ranging from $16.75 million to $35.38 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $9.40 million for the quarter, compared to analyst estimates of $6.13 million. BioCryst Pharmaceuticals had a negative return on equity of 323.86% and a negative net margin of 150.24%. The firm’s revenue was up 95.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.31) EPS.

A number of analysts recently commented on BCRX shares. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Saturday, May 6th. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Monday, May 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, May 19th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. BioCryst Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $8.29.

A number of hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares in the last quarter. Comerica Bank increased its stake in BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock worth $100,000 after buying an additional 2,552 shares in the last quarter. American International Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 45,230 shares of the biotechnology company’s stock worth $380,000 after buying an additional 2,989 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in BioCryst Pharmaceuticals by 5.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 60,126 shares of the biotechnology company’s stock worth $505,000 after buying an additional 3,339 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after buying an additional 7,568 shares in the last quarter. 84.57% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 0.60% on Thursday, hitting $5.06. The company had a trading volume of 101,834 shares. BioCryst Pharmaceuticals has a one year low of $3.30 and a one year high of $9.25. The stock has a 50 day moving average of $5.65 and a 200-day moving average of $6.39. The stock’s market capitalization is $406.93 million.

TRADEMARK VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/27/5-39-million-in-sales-expected-for-biocryst-pharmaceuticals-inc-bcrx-this-quarter.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.